Pibrentasvir

CHEMBL3545123 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1113.2 g/mol

LogP

7.4

Phase

4

A direct-acting antiviral used in combination with glecaprevir to treat chronic hepatitis C infections of multiple genotypes. It blocks a protein the virus needs to assemble and release new viral particles.

Moleküler Ağırlık

1113,2000 g/mol

LogP

7,40

TPSA

200,00 Å²

Lipinski RO5

Başarısız

Terapötik Alanlar

Chronic Kidney Disease HIV/AIDS Hepatitis C Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc2cc([C@H]3CC[C@H](c4cc5nc([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)[nH]c5cc4F)N3c3cc(F)c(N4CCC(c5ccc(F)cc5)CC4)c(F)c3)c(F)cc2[nH]1)[C@@H](C)OC

InChI

InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1

Molecular Formula

C57H65F5N10O8

HBD / HBA

4 / 17

Döndürülebilir Bağlar

17

Ağır Atomlar

80

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A direct-acting antiviral used in combination with glecaprevir to treat chronic hepatitis C infections of multiple genotypes. It blocks a protein the virus needs to assemble and release new viral particles.

Yes, Pibrentasvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545123. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 58031952. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Pibrentasvir PillFYI'da

Yapı

Hızlı Veriler

Formül: C57H65F5N10O8
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.